Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120.

Salivary agglutinin (SAG) is a high molecular mass glycoprotein (340 kDa) that plays important roles in innate immunity. SAG has been found to specifically inhibit HIV-1 infectivity and to bind to virus through the envelope protein gp120. Although SAG binds to gp120 of the virus, the exact nature of this binding has not been characterized. Using surface plasmon resonance technology, we have found that SAG interacts with recombinant envelopes derived from diverse HIV-1 isolates with K(D) values ranging from 10(-7) to 10(-10) M, comparable to gp120-sCD4 binding. Furthermore, SAG binding to gp120 is Ca(2+) dependent. sCD4 prebound to gp120 failed to abrogate SAG binding, suggesting a distinct mechanism for SAG inhibition of HIV-1 infectivity. Inhibition by monoclonal antibodies specific for carbohydrates also implicates the involvement of carbohydrates in the interaction between SAG and gp120. These results argue that the anti-HIV-1 activity of SAG is due to carbohydrate-mediated binding to gp120. A demonstration that SAG is related to lung scavenger receptor, gp-340, further suggests the roles of SAG in preventing pathogen invasion at the entry portal and raises its potential as an anti-HIV-1 drug candidate.

[1]  H. Gewurz,et al.  Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. , 2000, The Journal of general virology.

[2]  H. Friedman,et al.  Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. , 1998, The Journal of infectious diseases.

[3]  H. Friedman,et al.  Human submandibular saliva specifically inhibits HIV type 1. , 1997, AIDS research and human retroviruses.

[4]  P. Fox,et al.  Saliva inhibits HIV-1 infectivity. , 1988, Journal of the American Dental Association.

[5]  A. Trkola,et al.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex , 1997, Journal of virology.

[6]  B. Prabhakar,et al.  Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. , 1991, AIDS research and human retroviruses.

[7]  D. Malamud,et al.  Saliva and inhibition of HIV-1 infection: molecular mechanisms. , 2002, Oral diseases.

[8]  D. Malamud,et al.  Streptococcal-host interactions. Structural and functional analysis of a Streptococcus sanguis receptor for a human salivary glycoprotein. , 1990, The Journal of biological chemistry.

[9]  Rebecca L Rich,et al.  Survey of the year 2003 commercial optical biosensor literature , 2005, Journal of molecular recognition : JMR.

[10]  K. Baar The National Movement to Halt the Spread of Multifamily Housing, 1890-1926 , 1992 .

[11]  D. Malamud,et al.  Differential distribution of salivary agglutinin and amylase in the Golgi apparatus and secretory granules of human salivary gland acinar cells , 1991, The Anatomical record.

[12]  R. Silverstein,et al.  Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human Saliva , 1998, The Journal of experimental medicine.

[13]  Q. Sattentau,et al.  Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.

[14]  C. Barr,et al.  Recovery of infectious HIV-1 from whole saliva. , 1992, Journal of the American Dental Association.

[15]  C. Broder,et al.  Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction , 1993, Journal of virology.

[16]  D. Malamud,et al.  Comparison of Streptococcus mutans and Streptococcus sanguis receptors for human salivary agglutinin. , 1990, Microbial pathogenesis.

[17]  A. Poustka,et al.  DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. , 2000, Cancer research.

[18]  S. Baron,et al.  Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva. , 1994, The New England journal of medicine.

[19]  J. Groopman,et al.  A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus , 1989, The Journal of experimental medicine.

[20]  U. Holmskov,et al.  Isolation and Characterization of a New Member of the Scavenger Receptor Superfamily, Glycoprotein-340 (gp-340), as a Lung Surfactant Protein-D Binding Molecule* , 1997, The Journal of Biological Chemistry.

[21]  P. Luciw,et al.  Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection , 1997, Journal of virology.

[22]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[23]  D. Dripps,et al.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. , 1995, The Journal of clinical investigation.

[24]  E. Vigoren,et al.  Parotid salivary basic proline-rich proteins inhibit HIV-I infectivity. , 2001, Oral diseases.

[25]  J. Rundegren,et al.  Characterization of a salivary agglutinin reacting with a serotype c strain of Streptococcus mutans. , 1983, European journal of biochemistry.

[26]  R. Lamont,et al.  Cloning and expression of a Streptococcus sanguis surface antigen that interacts with a human salivary agglutinin , 1988, Infection and immunity.

[27]  D. Shugars Endogenous mucosal antiviral factors of the oral cavity. , 1999, The Journal of infectious diseases.

[28]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[29]  D. Malamud,et al.  gp340 (SAG) binds to the V3 sequence of gp120 important for chemokine receptor interaction. , 2004, AIDS research and human retroviruses.

[30]  U. Holmskov,et al.  Human salivary agglutinin binds to lung surfactant protein-D and is identical with scavenger receptor protein gp-340. , 2001, The Biochemical journal.

[31]  L. Epstein,et al.  Interaction of HIV-1 and human salivary mucins. , 1994, Journal of acquired immune deficiency syndromes.

[32]  C. Nilsson,et al.  Salivary Agglutinin, Which Binds Streptococcus mutansand Helicobacter pylori, Is the Lung Scavenger Receptor Cysteine-rich Protein gp-340* , 2000, The Journal of Biological Chemistry.

[33]  M. Rosenberg,et al.  The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site , 1991, Journal of virology.

[34]  S. Baron,et al.  Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. , 1999, Archives of internal medicine.

[35]  D. Malamud,et al.  A MODEL FOR SALIVA-MEDIATED BACTERIAL AGGREGATION , 1981 .

[36]  M. Harmsen,et al.  Antiviral activities of lactoferrin. , 2001, Antiviral research.

[37]  A. Poustka,et al.  Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. , 1999, Proceedings of the National Academy of Sciences of the United States of America.